PMID- 31754305
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231014
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - Long Non-Coding RNA CDKN2B-AS1 Facilitates Laryngeal Squamous Cell Cancer Through 
      Regulating miR-497/CDK6 Pathway.
PG  - 8853-8862
LID - 10.2147/OTT.S221620 [doi]
AB  - BACKGROUND: CDKN2B antisense RNA 1 (CDKN2B-AS1), a long noncoding RNA, was 
      reported to play crucial roles in the progression of multiple cancers. However, 
      the functional roles and regulatory mechanism of CDKN2B-AS1 in human laryngeal 
      squamous cell cancer (LSCC) remain unclear. The goals of this study were to 
      investigate biological roles and underlying mechanisms of CDKN2B-AS1 in LSCC. 
      METHODS: The expressions of CDKN2B-AS1, miR-497 and cyclin-dependent kinase 6 
      (CDK6) were detected in LSCC tissues and cell lines by real-time quantitative PCR 
      (qRT-PCR). The effects of CDKN2B-AS1 on LSCC cell proliferation, apoptosis, 
      migration and invasion were examined by corresponding experiments. Bioinformatics 
      analysis and luciferase activity assay were applied to analyze the interaction 
      between CDKN2B-AS1 and miR-497. RESULTS: The expression of CDKN2B-AS1 was 
      significantly higher in LSCC tissues than in adjacent normal tissues. Higher 
      CDKN2B-AS1 was closely associated with lymph node metastasis and advanced 
      clinical stage. Moreover, CDKN2B-AS1 knockdown by siRNA significantly inhibited 
      the proliferation, induced cell apoptosis, and suppressed migration and invasion 
      in LSCC cells. Mechanically, CDKN2B functions as an oncogenic lncRNA in LSCC via 
      regulating miR-497/CDK6 axis. CONCLUSION: The observations in this study identify 
      CDKN2B-AS1 an oncogenic role in the tumorigenesis of LSCC by regulating 
      miR-497/CDK6 axis and indicate that it may serve as a potential target for LSCC 
      treatment.
CI  - (c) 2019 Cui et al.
FAU - Cui, Xiangyan
AU  - Cui X
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Hospital of Jilin 
      University, Changchun 130021, People's Republic of China.
FAU - Yu, Tingting
AU  - Yu T
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Hospital of Jilin 
      University, Changchun 130021, People's Republic of China.
FAU - Shang, Jing
AU  - Shang J
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Hospital of Jilin 
      University, Changchun 130021, People's Republic of China.
FAU - Xiao, Dong
AU  - Xiao D
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Hospital of Jilin 
      University, Changchun 130021, People's Republic of China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Hospital of Jilin 
      University, Changchun 130021, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20191029
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6825505
OTO - NOTNLM
OT  - CDK6
OT  - CDKN2B-AS1
OT  - laryngeal squamous cell cancer
OT  - long noncoding RNA
OT  - miR-497
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/11/23 06:00
MHDA- 2019/11/23 06:01
PMCR- 2019/10/29
CRDT- 2019/11/23 06:00
PHST- 2019/07/02 00:00 [received]
PHST- 2019/09/24 00:00 [accepted]
PHST- 2019/11/23 06:00 [entrez]
PHST- 2019/11/23 06:00 [pubmed]
PHST- 2019/11/23 06:01 [medline]
PHST- 2019/10/29 00:00 [pmc-release]
AID - 221620 [pii]
AID - 10.2147/OTT.S221620 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 Oct 29;12:8853-8862. doi: 10.2147/OTT.S221620. 
      eCollection 2019.